Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836043 | 0.91 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL3877771 | 0.90 | MCHR1 (0.98) | MCHR1 | |
| SCHEMBL4490912 | 0.89 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL3872311 | 0.88 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL3875412 | 0.87 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL3839666 | 0.85 | MCHR1 (0.91) | MCHR1 | |
| SCHEMBL3831854 | 0.84 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5873536 | 0.84 | MCHR1 (0.80) | MCHR1 | |
| SCHEMBL3837260 | 0.83 | MCHR1 (0.78) | MCHR1 | |
| SCHEMBL13824241 | 0.82 | MCHR1 (0.84) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553089-B1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMA CO LTD (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | MC1R, MCHR1, MCHR2 | MCHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.